III.A viable strategy could also comprise two consecutive monotherapies, an initial 14 day anti-CD3 monotherapy followed by a consecutive 14 day anti-TNF-α monotherapy, which has been shown to be safe and effective in the IDDM rat model of human T1DM [50]. This evidence concerns the gene TNF and type 1 diabetes mellitus.